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Erythropoiesis stimulating agent (ESA) treatment has been a
major advance in the care of patients with kidney disease,
resulting in reduced symptoms and blood transfusions, and
improved quality of life. Recent studies, however, have
indicated that attempts to treat to near normal Hgb targets
may result in increased risk for death or cardiovascular
events. This had led to an appropriate increase in caution,
and avoidance of Hgb targets greater than 13 g/dl. There is,
however, a great lack of understanding of the mechanisms of
harm with more intensive ESA treatment. One avenue for
investigation in medicine is analysis of outlier experience. In
this article we will consider the experience of a group of
dialysis units in Berlin, Germany, that have achieved
outstanding patient outcomes despite targeting normal Hgb
levels with ESA treatment. The purpose is to explore ancillary
treatment processes that could mitigate any harmful effects
of ESA therapy. We do not seek to propose that treatment
with ESAs to higher Hgb targets is safe, but rather to use this
outlier experience to gain knowledge and to generate
hypotheses to be tested in future studies.
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Treatment of renal anemia with erythropoiesis-stimulating
agents (ESAs) greatly improves patients’ lives by reducing
unpleasant symptoms and the need for blood transfusions.1
This is generally achieved by partial anemia correction with
Hb targets below Hb concentrations found in normal
individuals. A series of studies have explored the possibility
that ESA treatment to achieve full anemia correction to
normal Hb levels would further improve patients’ outcomes.
Although several of these studies have found improvement in
quality of life (QOL), few have found any significant
improvement in key outcomes such as mortality or
cardiovascular events. Moreover, the three largest rando-
mized controlled trials (RCTs) have found increased risk
for adverse outcomes when targeting Hb levels above
13 g/100 ml.2–4 As a result, the National Kidney Foundation’s
Kidney Disease Outcomes Quality Initiative anemia guide-
lines5 recommend avoiding Hb targets 413 g/100 ml during
ESA treatment.
The mechanism by which ESA treatment to higher Hb
targets could be harmful has not been elucidated, but several
hypotheses have been proposed.6 These include, but are not
limited to, (1) the toxic effects of increased whole blood
viscosity on the cardiovascular system, (2) enhanced platelet
function and activation, (3) increased blood pressure, and
(4) a direct toxic effect of the ESA itself. Current studies are
investigating the various mechanistic pathways with a goal of
better understanding how to optimize ESA treatment. Until
such studies are completed, one avenue for understanding
ESA treatment from a different perspective is a consideration
of the experience at centers that have used ESA treatment
with full anemia correction without finding any apparent
harm. In this paper, we will consider the experience of Hampl
and colleagues, from Berlin, Germany,7–10 who for 11 years
have employed ESA treatment in hemodialysis patients to
normal Hb targets; with remarkably positive results. The
purpose of this analysis is not to negate the findings of
rigorous RCTs, which have clearly indicated harm with
treatment to higher Hb targets. Rather, we intend to consider
the Berlin experience to explore alternative treatment
processes that might mitigate any harmful effects of ESA
treatment and to generate new hypotheses for better under-
standing how ESA treatment could be optimized. First,
however, we will briefly review the current literature of
published RCTs.
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RCTs OF ESA TREATMENT TO HIGHER Hb TARGETS
There are currently 12 published RCTs that have compared
lower to higher Hb targets,2–4,11–19 four in hemodialysis and
eight in nondialysis chronic kidney disease. Outcomes tested
have included risk for mortality, cardiovascular end points,
left ventricular hypertrophy (LVH), and QOL. The majority
of studies have indicated a signal of improved QOL, as
measured by patient survey or functional testing. In fact,
in the CREATE study, an RCT of 600 patients with
nondialysis chronic kidney disease, a significant improve-
ment in QOL occurred with Hb normalization over a broad
spectrum of measures of dimensions of QOL. However, it is
important to note that most of these studies have been open
label, which might limit the ability to rigorously assess QOL.
In addition, other criticisms in study design and reporting as
to QOL have been put forth by the US Food and Drug
Administration.20
None of the published RCTs have found significant
improvement in outcomes other than QOL with higher Hb
targets. Of great concern has been a trend toward increased
risk for death and cardiovascular events with Hb targets above
13 g/100 ml. Most notably, the three largest studies, which
included over 3000 patients, all found strong trends toward
increased mortality risk. The Correction of Hemoglobin and
Outcomes in Renal Insufficiency (CHOIR), Cardiovascular
Risk Reduction by Early Anemia Treatment With Epoetin beta
(CREATE), and Normal Hematocrit Cardiac Trials, in both
nondialysis chronic kidney disease and hemodialysis, found
increased risk for death of 21–48% with normal Hgb
targets.2–4 Taken together, these findings provide a remarkably
consistent thread of evidence that has implicated ESA
treatment to higher Hb targets with adverse outcomes.
THE EXPERIENCE AT CHARITE UNIVERSITY CLINIC, BERLIN
In contrast to the published RCTs, Hampl and colleagues at
the Charite University Clinic in Berlin have had outstanding
results with ESA treatment and Hb normalization. Much of
this work has been previously reported.7–10,21 A total of 330
in-center hemodialysis patients were studied with a multi-
faceted treatment that centered on epoetin-b treatment to a
target Hb level of 14.5 g/100 ml in men and 13.5 g/100 ml in
women. A second aspect of treatment was intensive cardiac/
antihypertensive therapy with b-blockers, angiotensin-
converting enzyme inhibitors, and angiotensin receptor
blockers (respective targets of 200 mg metoprolol, 10 mg
ramipril, and 32 mg candesartan). Another ancillary treat-
ment was intensive i.v. iron therapy with sodium ferric
gluconate to iron targets significantly higher than typically
used. In addition, there was optimized correction of
metabolic acidosis as well as i.v. administration of vitamins
including L-carnitine, vitamins B6 and B12, and folic acid.
These were the metabolic conditions for optimized oxygen
utilization in the presence of full anemia correction.20
The study population had a mean age of 58 years, with
heart disease commonly present; 39% had coronary artery
disease, 16% severe valvular disease, left ventricular ejection
fraction less than 35 in 14%, cerebrovascular disease in 8.5%,
and peripheral vascular disease in 21.5%. A total of 56.4%
of patients were classified initially as New York Heart
Association class III or higher. Patients were on dialysis for
an average of approximately 13 years. The population had a
relatively low percentage of diabetics (26%) and a large
number of arteriovenous fistulae as dialysis access (83.9%).
The mean follow-up lasted 6.4±1.2 years; patients
achieved a mean Hb of 14.3±1.5 g/100 ml. The mean dose
of epoetin-b was 153±27 IU/kg/week/patient during correc-
tion phase and 68±23 IU/kg/week/patient during the main-
tenance phase. The mean weekly iron dose was 36±18 mg.
Iron was used initially if deficiency was noted (up to 120 mg
iron III–sodium–gluconate complex weekly during correction
phase). Epoetin-b was used intravenously only after iron
repletion was accomplished. Iron and epoetin-b were never
interrupted, but reduced to maintain Hb in the normal range
of 13.5–14.5 g/100 ml.
Maximal doses of b-blockers were achieved in 75% of
patients, angiotensin-converting enzyme inhibitors in 77%
and angiotensin receptor blockers in 78%. This triple cardiac/
hypertension therapy resulted in mean predialysis systolic
blood pressure of 132±12, diastolic blood pressure of
81±5 mm Hg, and a pulse rate of 61.8±6/min.
Echocardiography demonstrated significant improve-
ments in all parameters: left ventricular mass index (LVMI),
ejection fraction, posterior wall thickness, and end diastolic
diameter; as well as intraventricular septal thickness. The
regression of LVH could be subdivided in four groups: group
I (33%) LVMI initially normal, could be maintained normal;
group II (30%) LVMI initially increased, responded with
complete regression; group III (20%) initial highly increased
LVMI, responded with partial regression; and group IV
(17%) were nonresponders. These results stand in stark
contrast to the consistent failure to achieve beneficial LVH
effects in ESA RCTs.2,11,22,23
In nearly 75% of new hemodialysis patients, LVH is
present.24 It is a strong predictor of subsequent mortality24–28
and makes volume management more difficult due to altered
pressure–volume properties. Hampl and colleagues found, by
multivariate analysis, that full correction of anemia and triple
cardiac/hypertension were significant and independent pre-
dictors for reduction of LVMI. In addition, mean New York
Heart Association functional class improved by nearly one
whole class. Nutritional status appeared to improve as body
mass increased significantly. Between February 1997 and July
2007, 82 patients died in the overall population of N¼ 330
patients: 9.4% (31 deaths) by cardiac causes, 12.4% (41
deaths) by non-cardiac causes, and 10 deaths by arterial
peripheral occlusions with septicemia.
In summary, Hampl and colleagues used ESA treatment
with full anemia correction, and achieved positive cardiac
effects and outstanding patient outcomes. As these findings
differ so greatly from the major RCTS of anemia correction
such as the CHOIR, CREATE, and NHCT studies,2–4 it might
be tempting to simply dismiss these results as an aberrant
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finding. To be sure, the evidentiary value of the Berlin
experience is quite minimal compared with well-powered
RCTs. But science is often well served by careful attention to
outlier experience. We can generate hypotheses from this
experience that could help to better understand the general
failure of Hb normalization studies and perhaps to design
subsequent studies that might allow the full potential of ESA
treatment to be reached. In the following sections, we will
consider how different aspects of the treatment used by
Hampl and colleagues might have helped mitigate potentially
harmful effects of Hb normalization.
THE EFFECT OF HYPERTENSION
Certainly we must begin by a consideration of blood pressure
effects of ESA treatment and the notably intensive anti-
hypertensive treatment employed by Hampl et al. Treatment
with ESAs is generally believed to result in approximately
30% of patients having worsening hypertension.29 Normal-
ization of Hb results further increases in blood pressure.
Phromminthikul et al., in a recent meta-analysis, considered
the literature of Hb normalization studies, and found that
higher compared with lower Hb targets resulted in significant
increases in blood pressure.30 As an example, in the CREATE
study, systolic blood pressure 4160 mm Hg was increased
50% in the normal Hb group.2 As hypertension is such a
clearly established cause of increased risk for death,
cardiovascular events, and LVH,31–33 one important hypoth-
esis to explain why ESA treatment to higher Hb targets has
been associated with increased risk is the attendant increase
in blood pressure. Failure to adequately control blood
pressure in Hb normalization studies has been an important
weakness of these studies. More pointedly, given the
importance of hypertension and its relationship to ESA
treatment, these studies have been woefully superficial and
deficient in their reporting of blood pressure and anti-
hypertensive medication use (Table 1).
Hampl and colleagues used very intensive cardiac/
antihypertensive therapy, treating with maximal doses of
b-blockers, angiotensin-converting enzyme inhibitors, and
angiotensin receptor blockers in the majority of patients. It is
likely that this differs not only from the RCTs of ESA
treatment, but from routine hemodialysis practice as well.
The result was normal mean predialysis blood pressure and
pulse. In fact, with this rigorous therapy, ESA treatment to
full Hb normalization was associated not only with no
increase in blood pressure, but rather a substantial decrease.
This avoidance of hypertension might explain the out-
standing outcomes achieved. It should be noted that the
specific antihypertensive agents, b-blockers, and angiotensin
system blockers have cardio protective effects that make them
particularly useful.
The success with LVH regression in this study merits
particular emphasis. As noted above, LVH is an independent
predictor of mortality and is remarkably common among
hemodialysis patients.24 The two major potentially remedi-
able risk factors identified by observational studies, for
development and progression of LVH in chronic kidney
disease, are anemia and hypertension.34 Therefore, it is
possible that a salutary effect of Hb normalization might be
counterbalanced and obscured by associated increases in
blood pressure. Hampl and colleagues, by coupling Hb
normalization to intensive antihypertensive treatment, might
have successfully managed both key LVH risk factors. Indeed,
the success in obtaining LVH regression in this study stands
in stark contrast with the failure to do so in previous Hb
normalization RCTs, where blood pressure control was
generally lax.2,11,22,23
The findings of Hampl and colleagues lead to an
important hypothesis; that ESA treatment with Hb normal-
ization must be coupled to intensive blood pressure
treatment. As Hampl’s study and experience did not include
a control group, it is possible that factors beyond anemia and
antihypertensive treatment might have explained the positive
findings. Only a well-powered RCT that properly isolated
these interventions could suitably test this hypothesis. The
reasonableness of performing such a study and the
willingness of funders and investigators in participating
would depend on several factors. First, how likely is it that the
intensive antihypertensive treatment as opposed to other
components of Hampl’s multifaceted approach was the
intervention that drove the improved outcomes? Second,
and perhaps most importantly, given the strong signal of
adverse outcomes, including increased mortality risk, from
previous Hb normalization RCTs, how great is the probability
Table 1 | Treatment and reporting of hypertension in major ESA studies
Study Blood pressure protocol
Quality of blood pressure
reporting in study publication
Quality of antihypertensive drug
reporting
Mean blood pressure
achieved high hgb group
(mm Hg)
Singh et al. 1432 Not reported Not reported Not reported Not reported
Besarab
et al.
1233 Not reported Poor, only mean for both groups
combined
Poor, only subjective notation of
use of cardiovascular drug classes
150/78 (combined groups)
Drueke et al. 600 Not reported Minimal, only mean baseline and
last BP values
Minimal reporting, only summary
data
136/79
Parfrey et al. 596 Predialysis diastolic BP
between 70 and 90 mm Hg
(measured weekly for 24
weeks, then every 4 weeks)
Minimal, only mean baseline and
last BP values
Poor, only % receiving
antihypertensive medications
141/80
BP, blood pressure; ESA, erythropoiesis stimulating agent.
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that intensive antihypertensive therapy would mitigate the
risk? Invariably this question must also raise the question of
whether all aspects of the Hampl approach must be tested
together in a combined multifaceted intervention. This will
be considered later. Third, what is the likelihood that unusual
aspects of this population might have explained the
surprising results; such as the low rate of diabetics, high rate
of arteriovenous fistula use, and small number of black
participants? This point will resonate with nephrologists in
the United States, where achieving adequate blood pressure
control in hypertensive often seems an elusive and frustrating
goal. Attempts to use the types and doses of antihypertensive
drugs employed by Hampl et al. are often accompanied by
intradialytic hypotension. Hampl et al. have previously
reported that a key to preventing symptomatic hypotension
during hemodialysis is optimized correction of metabolic
acidosis—especially a normal arterial pCO2 during hemo-
dialysis.35
One is reminded of the remarkable experience of Charra
et al.’s group in Tassin, France, where long, slow dialysis
treatments result in excellent blood pressure control and a
much longer average lifespan than in the United States.36 In
addition, Chan et al.37 have shown that nocturnal dialysis
greatly improves blood pressure and LVH. But neither of
these observations would explain well how Hampl and
colleagues succeed with their intensive antihypertensive
treatment, as their dialysis treatment time was 4 h, only
slightly greater than in the United States. The ability to test
this regimen in the United States and many other countries
may depend on the practicability of employing such an
intensive antihypertensive regimen, although avoiding inter-
dialytic hypotension.
THE ROLE OF IRON DEFICIENCY AND PLATELETS
A second aspect of Hampl’s group’s treatment that is atypical
is the intensive i.v. iron therapy. Patients are treated with i.v.
iron regularly, to achieve transferrin saturation of 50%, well
above the National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative target of to achieve transferrin
saturation 420%.38 In this section we will explore the
possibility that this rigorous approach to iron management
might have beneficial effects that could protect against
thrombotic risks during ESA therapy with normalization
of Hb.
It is noteworthy that none of the three RCTs that found
harm with targeting of higher levels of Hb2–4 included
anything approaching intensive iron treatment; in fact, they
were all quite passive as to iron management (Table 2). This
is a highly relevant issue in that ESA treatment induces a
massive transfer of iron from storage tissues to the expanding
erythron. Correcting Hb beyond the usual therapeutic
targets, all the way to full normalization, results in great
demands for iron, making iron deficiency an expected
occurrence. The failure to adequately address iron status in
these three key RCTs might at least partially explain the
adverse outcomes. We will develop a hypothesis that iron
deficiency that occurs during ESA treatment to normal Hb
targets could result in increased platelet counts, and that
increased platelet number and function could raise the risk
for atherothrombotic complications.
It has long been known that treatment with ESAs is
associated with an increase in platelet counts. Eschbach
et al.39 found that treatment with epoetin alfa to maintain
Hct 35±3% in hemodialysis patients resulted in an increase
in mean platelet counts. Similarly, Beguin et al.40 treated 61
hemodialysis patients with epoetin and found a significant
increase in mean platelet count from 220±80 to 245±102
after 14 days of treatment, with chronic stabilization at these
levels. These findings parallel earlier observations from
animal studies, where ESA treatment (especially high doses)
led to an increase in platelet counts which returned to normal
in the weeks after discontinuation.41,42 Furthermore, the
effect of ESAs on increasing platelet counts has been
exploited therapeutically when thrombocytopenia occurs in
liver disease or among children with sarcomas. In these
settings, ESA treatment has been used to reduce platelet
numbers.43–45
The mechanism by which ESA treatment leads to an
increase in platelet count is not completely understood.
However, ESA-induced iron-restricted erythropoiesis is
certainly a major factor. As discussed above, ESA treatment
to raise Hb requires a large amount of iron, raising Hb all the
way to normal requires an even greater amount, routinely
causing iron deficiency. Iron deficiency is an important and
Table 2 | Treatment and reporting of iron in major ESA studies
Study Iron management protocol
Quality of iron test reporting in
study publication Quality of iron drug reporting
Mean achieved iron
indices high Hgb group
Singh et al. 1432 Not reported Not reported Not reported Not reported
Besarab
et al.
1233 Unclear Poor, only baseline and 12 month
results reported
Fair, number of patients treated
and doses in the final 6 months
reported
Not reported
Drueke et al. 600 Left to discretion of
investigators
None Minimal reporting, only
summary data
None reported
Parfrey et al. 596 Transferrin saturationX20%
(measured biweekly for 24
weeks, then every 4 weeks)
Fair, baseline, and last TSAT and %
TSAT o20%, but no interim values
and no results for ferritin
Poor, only % receiving IV iron at
baseline and end of study
34.6±14.9 (%)
BP, blood pressure; ESA, erythropoiesis stimulating agent.
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predictable cause of an increase in platelet count.46 What
occurs with iron deficiency is a reactive thrombocytosis.47
Moreover, absolute thrombocytosis is observed in approxi-
mately 30% of patients with iron deficiency.48 In the past, the
increase in platelet count with iron deficiency was not
thought of as a cause of adverse events, but studies indicate
that the increase in platelet count with iron deficiency could
result in thromboembolic complications.49,50 Treatment of
iron deficiency might be expected to lower platelet counts.
Indeed, with oral or i.v. iron administration, platelet counts
often decrease significantly.51–55 Soto et al. found that with
iron treatment, 65% of patients’ thrombocytosis resolved in
o28 days. Loo et al. studied the interaction of ESA
treatment, iron and platelet counts in rats. Within days of
initiation, ESA treatment resulted in a decrease in functional
and storage iron pools and an increase in platelet counts.
When the rats were supplemented with iron, no increase in
platelet count occurred with ESA therapy.56 As ESA treatment
often causes iron deficiency, and as iron deficiency results in
increased platelet counts, the next question naturally
becomes one of whether increased platelet counts are
harmful.
Platelets is important in atherothrombotic events, as is
clearly evidenced by the beneficial role of antiplatelet therapy
in myocardial infarction and stroke.57–59 As patients with
kidney disease have a great prevalence of atherosclerotic
disease, a potential cardiovascular pathologic role of platelets
is highly relevant. Vascular intimal injury exposes thrombo-
genic subendothelial substances to flowing blood. The
platelet–vessel wall interaction is mediated primarily by von
Willebrand factor, a protein synthesized by endothelial cells
and megakaryocytes. Activated platelets synthesize cycloox-
ygenase (TXA2), the potent platelet activator and vasocon-
strictor. In the final phase of platelet activation, the process of
aggregation, fibrinogen, or von Willebrand factor binds to
specific platelet membrane receptors that are located in the
GP IIb/IIIa integrin complex. When two platelets with
functional (only in activated plateles) GP IIb/IIIa each bind
the same fibrinogen molecule, fibrinogen can form a bridge
between the two platelets. Each platelet has about 50,000 GP
IIb/IIIa-binding sites, so numerous activated platelets
recruited to the site of vascular injury can rapidly form an
occlusive aggregate. In patients with kidney disease, where
atherosclerotic vascular disease is so prevalent, the vascular
system may contain multiple areas of vulnerable or ulcerated
plaque that is at risk for thrombotic activation.
The relationship between ESA treatment, Hb normal-
ization, elevation in platelet counts, and outcomes was the
subject of a recent analysis. Streja et al. studied the records of
a large dialysis provider with 40,787 hemodialysis patients
treated with ESAs.60 The authors found that iron status was
significantly negatively correlated with platelet count. The
relationship was continuous and linear, the greater the iron
deficiency, the higher the mean platelet count. Given recent
RCT evidence of adverse outcomes with ESA treatment
to higher Hb targets, the investigators were particularly
interested in the relationship between Hb levels and
outcomes. Importantly, they found that patients with Hb
413 had a greater risk for mortality compared with patients
with lower Hb (in the 12–13 g/100 ml range). However, the
increased risk for death was only present when the elevated
Hb was accompanied by platelet counts 4300,000; and there
was no increase in risk with higher Hb levels when platelet
counts were less than 300,000.60 Similarly, in a study of ESA
treatment in cancer patients treated with chemotherapy,
treatment with i.v. iron significantly reduced the risk of
platelet counts greater than 350,000. Moreover, platelet
counts greater than 350,000 were associated with a fourfold
increase in the incident rate of thromboembolic events
(incident risk reduction (IRR): 4.4, P¼ 0.001). In this study,
i.v. iron treatment reduced the risk for thromboembolic
events by 40%. This effect appeared to be mediated through
lowering of platelet counts, as statistical significance was lost
after adjusting for increased platelet counts.61,62
Taken together, the above studies suggest that during ESA
treatment, iron deficiency could result in an increase in
platelet count that may contribute to an increase in
thrombotic risk. A slight extension, which should be
considered simply a hypothesis, is that adverse outcomes
found in ESA normalization studies might be due in part to
this phenomenon. This hypothesis could at least partially
explain the outstanding outcomes of Hampl’s patients treated
to a target Hb of 14 g/100 ml, but with prevention of iron
deficiency. In their patients, iron treatment was associated
with platelet counts in the normal range
(187,522±54,000 mm3). Their intensive iron treatment stood
in stark contrast to the passive iron management employed in
the Hgb normalization RCTs. This hypothesis, whereas
biologically plausible, requires testing in interventional
studies.
One point of caution should be noted regarding this
hypothesis on i.v. iron and a potential protective effect. In the
previous noted normal hematocrit cardiac trial,4 increased
i.v. iron use was not protective, but was actually found to be a
risk factor for adverse outcomes. This result must be viewed
with some skepticism. Iron management and treatment data
collection were at best incomplete and partially completed
after study completion with the negative results already
known. However, rather than simply dismissing the findings,
it suggests a need for further study of this complex subject.
METABOLIC CONTROL OF OXYGEN UTILIZATION
Special attention was given by the Berlin group to optimized
oxygen utilization during total anemia correction with ESA
treatment. Oxygen exhaustion from erythrocytes to tissue
cells, especially cardiomyocytes, depends on acid/base status.
The correction of metabolic acidosis was adapted to every
patient individually; patients came to dialysis treatment with
a serum bicarbonate of X23 mmol/l. In addition, energy
generation from fatty acids (adenosine triphosphate produc-
tion) (the most important energy source of the heart)
depends on L-carnitine concentration within the cell.
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L-Carnitine is essential in hemodialysis patients, but may be
deficient due to L-carnitine lost during the dialysis process
and reduced renal L-carnitine production.63 L-Carnitine, folic
acid, and vitamins B6 and B12 were supplemented in Hampl’s
hemodialysis patients.21 These interventions may have con-
tributed to improved oxygen utilization at higher Hgb levels.
Erythropoiesis-stimulating agent dosage
The dose of ESA required by patients in the Berlin centers
was considerably less than what is typical in the United
States. This is likely a result of intensive iron treatment and
improved ESA responsiveness related to ancillary treatments
as discussed above. The reduced ESA dose requirement could
relate to the excellent patient outcomes. One hypothesis for
adverse outcomes in Hgb normalization studies has been a
possible direct toxic effect of high ESA doses.6 Zhang et al.64
found ESA dose to be an independent predictor of mortality
in a study of over 90,000 hemodialysis patients. It is unclear
whether ESA dose truly is involved in this relationship. At
this time, it remains a viable hypothesis, worthy of study. To
the extent that higher doses of ESAs truly are harmful, part of
the positive experience of the Berlin group could be explained
by avoidance of such doses.
RECONCILIATION BETWEEN THE HAMPL GROUP OUTCOMES
AND THE MAJOR RCTs OF Hgb NORMALIZATION
The three largest ESA treatment RCTs that compared Hb
normalization to more modest levels of Hb correction all found
important trends toward worse outcomes with the higher Hb
targets. In contrast, Hampl’s group has achieved outstanding
clinical outcomes with the same full Hb correction. It would be
easy to dismiss the results of Hampl as the RCTs carry much
greater evidentiary weight. But the responsibility of medical
science is to try to understand aberrant results, and to fully
explore difference in interventions that could improve treat-
ment of patients. This has been the purpose of this report; not
to dismiss the results of the major RCTs, but rather to generate
hypotheses for ancillary interventions that might help ESA
treatment to reach its full potential.
We have identified particular treatment processes: (1)
intensive cardiac/antihypertensive therapy; (2) aggressive
iron management; (3) attention to optimized oxygen
utilization (optimized correction of metabolic acidosis and
supplementation of substances, which are involved in energy
metabolism (L-carnitine, vitamins B6 and B12, and folic
acid)); and (4) avoidance of very high ESA doses, that
clearly differentiated treatment by Hampl’s group from
that used in the ESA RCTs (see Figure 1). This raises the
vital question of whether it would be considered reasonable
and/or safe to conduct new RCTs to test ESA treatment
with Hb normalization coupled with these additional
interventions. The safety signals identified with Hb normal-
ization in the three major RCTs led the National Kidney
Foundation’s Kidney Disease Outcomes Quality Initiative
anemia guidelines group to issue a new, evidence-based
guideline, recommending avoidance of Hb targets 413 g/
100 ml. However, this guideline is based on the RCTs, studies
that probably were not attentive enough to blood pressure
and iron management. We believe that the experience of
Hampl’s group suggests great promise for improving
patient outcomes. Because of this, we would suggest that
sufficient equipoise still exists to conduct additional RCTs of
Hb normalization, as long as special precautions and
adequate data safety monitoring are in place. In particular,
the role of intensive cardiac and antihypertensive treatment
and effective iron management should be coupled to Hgb
normalization.
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